iDEL Therapeutics
PrivateLast Round
Seed
Mar 17, 2026
Total Funding Raised
$10.4M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
iDEL Therapeutics operates in Healthcare & Life Sciences and is based in Dortmund. Its latest recorded funding round was a Seed round in March 2026.
iDEL Therapeutics is a biotechnology company developing a pipeline of cancer therapeutics that are delivered directly into the cytosol of tumor cells using a proprietary synthetic shuttle platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
iDEL Therapeutics Comparables
Compare iDEL Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Libera Bio | 88% | |
| Xelcis Bio, Inc. | 87% | |
| CyGenica | 84% |
For institutional investors. Book with your work email.
iDEL Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
iDEL Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| NRW.Venture | Seed |
| KHAN Technology Transfer Fund II | Seed |
| BioMedPartners | Seed |
| Gründerfonds Ruhr | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 17, 2026
$11M raised in Seed round.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withNov 9, 2026
iDEL Therapeutics GmbH partners with Daiichi Sankyo, Inc. on a multi-year collaboration in Germany to use a synthetic shuttle platform for the preclinical evaluation of a multi-drug conjugate for selected solid tumors.
- partners_withNov 9, 2026
iDEL Therapeutics GmbH partners with Daiichi Sankyo Europe GmbH on a multi-year collaboration to evaluate a multi-drug conjugate using a synthetic shuttle platform for select solid tumor indications in Germany on Nov 9th '26.
- is_developingNov 9, 2026
iDEL Therapeutics GmbH enters a global research collaboration with Daiichi Sankyo to develop a multi-drug conjugate for targeted cytosolic delivery into solid tumor cells, with a multi-year collaboration focused on preclinical evaluation in Germany on Nov 9th '26.
For institutional investors. Book with your work email.
iDEL Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about iDEL Therapeutics's valuation, stock price, and market status.
Is iDEL Therapeutics a public or private company?
iDEL Therapeutics is a private company.
What is the current stock price of iDEL Therapeutics?
iDEL Therapeutics is a private company, so its shares have no public market price. Caplight tracks iDEL Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is iDEL Therapeutics worth (valuation)?
Valuation information for iDEL Therapeutics is not publicly available.
Can I buy iDEL Therapeutics stock?
iDEL Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was iDEL Therapeutics's last funding round?
iDEL Therapeutics's most recent funding round was Seed on March 17, 2026.
Who are the main investors in iDEL Therapeutics?
Key investors in iDEL Therapeutics include BioMedPartners.
Will iDEL Therapeutics IPO soon?
No public IPO plans have been announced for iDEL Therapeutics.
How can I track iDEL Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in iDEL Therapeutics's shares on secondary markets.